Latest news about Boston Commerce
Boston Commerce
5.25
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M-8.06%
6M-49.81%
1Y-27.49%
5Y-74.88%
More news about Boston Commerce
10Jun 26
Boston Commerce reports FY26 loss, qualified audit opinion
Boston Commerce Limited reported a net loss of ₹717.61 lakh for FY26, with auditors issuing a qualified opinion due to material asset write-offs and unpaid TDS dues. The company's net worth turned negative to ₹127.15 lakh, raising doubts about its ability to continue as a going concern.
01Jun 26
Boston Commerce board to consider share capital reduction
Boston Commerce Limited will hold a board meeting on June 05, 2026, to consider a proposal for reducing its share capital, subject to approvals under the Companies Act, 2013.
30May 26
Boston Commerce reports net loss of ₹58.08 lakh in FY26
Boston Commerce Limited reported a net loss of ₹58.08 lakh for the financial year ended March 31, 2026, compared to a net loss of ₹54.73 lakh in the previous year. Revenue from operations for the full fiscal year stood at ₹48.37 lakh, with zero revenue recorded in the quarter ended March 31, 2026. The Board of Directors approved the audited standalone financial results on May 30, 2026. Statutory auditors M/s. Sunit M Chhatbar & Co issued an unmodified opinion but noted the company did not make any payment of TDS dues during FY26. Total assets decreased to ₹892.61 lakh, while shareholders' funds stood at ₹532.38 lakh.
17Feb 26
Boston Bio Systems Limited Officially Changes Name to Boston Commerce Limited Effective February 20, 2026
Boston Bio Systems Limited has successfully completed its name change to Boston Commerce Limited, effective February 20, 2026. The BSE and Ministry of Corporate Affairs have approved the transformation, with the exchange maintaining scrip code 531458. The company's CIN L62013GJ1995PLC025476 and legal status remain unchanged, ensuring continuity for all stakeholders and market operations.
13Feb 26
Boston Commerce Limited Reports Q3FY26 Results with Revenue Decline and Net Loss
Boston Commerce Limited reported Q3FY26 results showing revenue of ₹5.85 lakhs, down from ₹24.47 lakhs in Q2FY26, resulting in a net loss of ₹1.44 lakhs. However, the nine-month period demonstrated strong recovery with total revenue of ₹48.37 lakhs and net profit of ₹6.51 lakhs, compared to zero revenue and ₹5.68 lakhs loss in the corresponding period last year. The company maintained its paid-up equity share capital at ₹700.22 lakhs with earnings per share of ₹0.09 for the nine-month period.
27Nov 25
Boston Bio Systems Limited Rebrands as Boston Commerce Limited
Boston Bio Systems Ltd. (BSE: 531458) has officially changed its name to Boston Commerce Limited, as approved by the Ministry of Corporate Affairs on November 27, 2025. The name change was authorized by shareholders through a Special Resolution at the Annual General Meeting on September 30, 2025. Recent financial data shows significant changes, with total assets increasing by 40.57% year-on-year to ₹14.90 crore, driven by an 89.58% rise in current assets. Non-current liabilities saw a dramatic 4500% increase, while total equity decreased by 9.23%.
14Nov 25
Boston Bio Systems Reports Q2 Profit, Appoints New Auditors
Boston Bio Systems Ltd. (BSE: BOSTONBIO) announced financial results for Q2 and H1 FY2025-26, showing significant improvement. Q2 revenue was ₹24.47 crore with a profit after tax of ₹3.94 crore, compared to a loss in the previous year. H1 revenue reached ₹42.52 crore with ₹7.95 crore profit. The company also appointed Mr. Shashank Kumar as Secretarial Auditor and Mr. Nishant Sharma as Internal Auditor for FY2025-26.
13Oct 25
Boston Bio Systems Limited Announces Key Leadership Changes in Company Secretarial Position
Boston Bio Systems Ltd. has appointed Ms. Nisha Yadav as the new Company Secretary and Compliance Officer, effective October 13, 2025. She replaces Ms. Mandeep Kaur, who has resigned from the position. Ms. Yadav is a qualified Company Secretary with over 4 years of experience in corporate law matters. The changes were approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee.
04Sept 25
Boston Bio Systems Announces Major Corporate Changes, Including New Auditor Appointment
Boston Bio Systems Ltd. (BSE: 531458) has announced significant corporate changes following a board meeting. The company appointed M/s Sunit M Chhatbar & Co. as the new Statutory Auditor, replacing M/s Nahar V & Company. The Board approved changes to the Memorandum of Association, expanding potential business activities to include IT services, agriculture, real estate, and e-commerce. A new set of Articles of Association was also approved. These changes are subject to shareholder approval at the upcoming 30th Annual General Meeting.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare Technologies
Nephrocare Health Services
Krsnaa Diagnostics
Suraksha Diagnostic
One Global Service Provider
3B BlackBio DX
Health X Platform
1,699.00
(-0.06%)
1,313.10
(-1.37%)
570.10
(+0.23%)
557.95
(-0.87%)
672.65
(+7.37%)
541.70
(-1.93%)
259.60
(-0.54%)
601.00
(-0.65%)
1,289.60
(+1.38%)
319.90
(+0.57%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
